DANA-FARBER CANCER INSTITUTE
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Mantle Irradiation for Hodgkin's Disease
- Conditions
- Hodgkin's Disease
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT00165269
- Locations
- πΊπΈ
Dana-Farber Cancer Center, Boston, Massachusetts, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
Treatment of Acute Lymphoblastic Leukemia in Children
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 498
- Registration Number
- NCT00165178
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-07-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 53
- Registration Number
- NCT00165334
- Locations
- πΊπΈ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy
- Conditions
- Hodgkin's Disease
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00165438
- Locations
- πΊπΈ
Brigham and Women's Hospital, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
Treatment of Childhood Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 491
- Registration Number
- NCT00165087
- Locations
- πΊπΈ
Ochsner Clinic, New Orleans, Louisiana, United States
π¨π¦McMaster University, Hamilton, Ontario, Canada
πΊπΈMaine Medical Center, Lewiston, Maine, United States
Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer
- Conditions
- Malignant TumorsSubcutaneous TumorsLymph Node Tumors
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT00165100
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
- Conditions
- Colorectal Adenocarcinoma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT00165217
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Breast Carcinoma
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT00165581
- Locations
- πΊπΈ
Brigham and Women's Hospital, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation
- Conditions
- Hodgkin's Disease
- Interventions
- Procedure: Echo/Stress Echo
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 210
- Registration Number
- NCT00165425
- Locations
- πΊπΈ
Brigham and Women's Hospital, Boston, Massachusetts, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
Sildenafil Citrate in Waldenstrom's Macroglobulinemia
- Conditions
- Waldenstrom's Macroglobulinemia
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00165295
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States